Does the neuropathology of human patients with variant Creutzfeldt-Jakob disease reflect haematogenous spread of the disease?

Neuroscience Letters

Volumn 348, Issue 1, 2003, Pages 37-40

  Armstrong, R A ^a   Cairns, N J ^b   Ironside, J W ^c   Lantos, P L ^d  

^a ASTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Blood vessels; Correlation; Prion protein deposits; Vacuolation; Variant Creutzfeldt Jakob disease

Indexed keywords

PRION PROTEIN;

ARTICLE; BRAIN BLOOD VESSEL; BRAIN CORTEX; CELL VACUOLE; CEREBELLUM; CORRELATION ANALYSIS; CREUTZFELDT JAKOB DISEASE; DENTATE GYRUS; DISEASE TRANSMISSION; HIPPOCAMPUS; HUMAN; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; ADULT; ANALYSIS OF VARIANCE; ATROPHY; BLOOD VESSEL; COMPARATIVE STUDY; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY;

ADULT; ANALYSIS OF VARIANCE; ATROPHY; BLOOD VESSELS; CEREBELLUM; CEREBRAL CORTEX; CREUTZFELDT-JAKOB SYNDROME; FEMALE; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PRPSC PROTEINS; VACUOLES;

EID: 0041883733     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00696-7     Document Type: Article

References (22)

1. Amouyel P., Vidal O., Launay J.M., Laplanche J.L. The apolipoprotein e alleles as major susceptibility factors for Creutzfeldt-Jakob disease. Lancet. 344:1994;1315-1318.
2. Armstrong R.A. The usefulness of spatial pattern analysis in understanding the pathogenesis of neurodegenerative disorders, with special reference to plaque formation in Alzheimer's disease. Neurodegeneration. 2:1993;73-80.
3. Armstrong R.A. Dispersion of classic β-amyloid deposits around blood vessels in Alzheimer's disease. Alz. Rep. 4:2001;103-108.
4. Armstrong R.A., Lantos P.L., Cairns N.J. Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt-Jakob disease. Neuropathology. 21:2001;266-271.
5. Armstrong R.A., Cairns N.J., Lantos P.L. The spatial pattern of prion protein deposits in Creutzfeldt-Jakob disease: comparison with β-amyloid deposits in Alzheimer's disease. Neurosci. Lett. 298:2001;53-56.
6. Armstrong R.A., Cairns N.J., Ironside J., Lantos P.L. The spatial patterns of prion protein (PrP) deposits in cases of variant Creutzfeldt-Jakob disease. Acta Neuropathol. 104:2002;665-669.
7. Brown P. The pathogenesis of transmissible spongiform encephalopathy: routes to the brain and the erection of therapeutic barricades. Cell. Mol. Life Sci. 58:2001;259-265.
8. Bruce M.E., McConnell I., Will R.G., Ironside J.W. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet. 358:2001;208-209.
9. Cervenakova L., Brown P., Hammond D.J., Lee C.A., Saenko E.L. Factor VIII and transmissible spongiform encephalopathy: the case for safety. Haemophilia. 8:2002;63-75.
10. Gray F., Chretien E., Cesaro P., Chetelain J., Beaudry P., Laplanche J.L., Mikol J., Bell J., Gambetti P., Degos J.D. Creutzfeldt-Jakob disease and cerebral amyloid angiopathy. Acta Neuropathol. 88:1994;106-111.
11. Hill A.F., Butterworth R.J., Joiner S., Jackson G., Rossor M.N., Thomas D.J., Frosh A., Tolley N., Bell J.E., Spencer M., King A., Al-Sarraj S., Ironside J.W., Lantos P.L., Collinge J. Investigation of variant Creutzfeldt-Jakob disease and other human prion disease with tonsil biopsy samples. Lancet. 353:1999;183-189.
12. Hoots W.K., Abramo C., Tankersley D. The impact of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease on plasma safety. Trans. Med. Rev. 15:2001;49-59.
13. Houston F., Foster J.D., Ching A., Hunter N., Bostock C.J. Transmission of BSE by blood transfusion in sheep. Lancet. 356:2000;999-1000.
14. Ironside J.W., Head M.W., Bell J.E., McCardle L., Will R.G. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathology. 37:2000;1-9.
15. Krasemann S., Groschup M.H., Harmeyer S., Hunsmann G., Bodemer W. Generation of monoclonal antibodies against human prion proteins in PrPO/O mice. Mol. Med. 2:1996;725-734.
16. Liberski P.P., Ironside J.W., McCardle L., Shering A. Ultrastructure analysis of the florid plaque in variant Creutzfeldt-Jakob disease. Folia Neuropathol. 38:2000;167-170.
17. MacGregor I.R., Drummond O. Species differences in the blood content of the normal cellular isoform of prion protein, PrPc, measured by time-resolved fluoroimmunoassay. Vox Sanguinis. 81:2001;236-240.
18. Maignien T., Lasmezasm C.I., Beringue V., Dormont D., Deslys J.P. Pathogenesis of the oral route of infection of mice with scrapie and bovine spongiform encephalopathy agents. J. Gen. Virol. 80:1999;3035-3042.
19. Pamphilon D.H., Rider J.R., Barbara J.A.J., Williamson L.M. Prevention of transfusion-transmitted cytomegalovirus infection. Trans. Med. 9:1999;115-123.
20. Turner M.L., Ironside J.W. New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. Blood Rev. 12:1998;255-268.
21. Watanabe R., Duchen L.W. Cerebral amyloid in human prion disease. Neuropathol. Appl. Neurobiol. 19:1993;253-260.
22. Will R., Ironside J.W., Zeidler M., Cousens S.N., Estebeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A., Smith P.G. A new variant of Creutzfeldt-Jakob disease in the United Kingdom. Lancet. 347:1996;921-925.